HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Figures Only Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shreve, P. D. Articles by Wahl, R. L. Search for Related Content PubMed PubMed Citation Articles by Shreve, P. D. Articles by Wahl, R. L.

Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign Variants¹

¹ Department of Internal Medicine, Division of Nuclear Medicine (P.D.S., R.L.W.)
² Department of Radiology (Y.A.), B1G412 University Hospital, University of Michigan Medical Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109
³ Department of Nuclear Medicine, Veterans Affairs Medical Center, Ann Arbor, Mich (P.D.S.).

	Abstract

Top Abstract INTRODUCTION TECHNIQUE GENERAL DISTRIBUTION OF FDG... SITES OF VARIABLE PHYSIOLOGIC... SITES OF BENIGN PATHOLOGIC... SUMMARY References

 
A rapidly emerging clinical application of positron emission tomography (PET) is the detection and staging of cancer with the glucose analogue tracer 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG). Proper interpretation of FDG PET images requires knowledge of the normal physiologic distribution of the tracer, frequently encountered physiologic variants, and benign pathologic causes of FDG uptake that can be confused with a malignant neoplasm. One hour after intravenous administration, high FDG activity is present in the brain, the myocardium, and—due to the excretory route—the urinary tract. Elsewhere, tracer activity is typically low, a fact that allows sensitive demonstration of tracer accumulation in many malignant neoplasms. Interpretive pitfalls commonly encountered on FDG PET images of the body obtained 1 hour after tracer administration can be mistaken for cancer. Such pitfalls include variable physiologic FDG uptake in the digestive tract, thyroid gland, skeletal muscle, myocardium, bone marrow, and genitourinary tract and benign pathologic FDG uptake in healing bone, lymph nodes, joints, sites of infection, and cases of regional response to infection and aseptic inflammatory response. In many instances, these physiologic variants and benign pathologic causes of FDG uptake can be specifically recognized and properly categorized; in other instances, such as the lymph node response to inflammation or infection, focal FDG uptake is nonspecific.

Index Terms: Emission CT (ECT), **.12163² • Fluorine • Neoplasms, diagnosis, **.30 • Neoplasms, emission CT (ECT), **.12163, **.30

	INTRODUCTION

Top Abstract INTRODUCTION TECHNIQUE GENERAL DISTRIBUTION OF FDG... SITES OF VARIABLE PHYSIOLOGIC... SITES OF BENIGN PATHOLOGIC... SUMMARY References

 
A rapidly emerging clinical application of positron emission tomography (PET) is the detection and staging of cancer with the glucose analogue tracer 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG). High target-to-nontarget ratios are obtained with most common neoplasms and allow detection of even anatomically occult neoplasms throughout the body (1). FDG uptake also occurs in nonmalignant tissue, notably the brain and heart, and FDG is excreted in the urinary tract. These sites of physiologic FDG activity are generally readily recognized; however, there are common sites of variable physiologic FDG uptake and benign pathologic FDG uptake that could be confused with malignant neoplasms.

The purpose of this article is to present these interpretive pitfalls so that a radiologist experienced in cross-sectional imaging can avoid false-positive diagnoses and recognize inherently nonspecific findings on FDG PET images obtained for oncologic diagnosis. These pitfalls include variable physiologic FDG uptake in the digestive tract, thyroid gland, skeletal muscle, myocardium, bone marrow, and genitourinary tract and benign pathologic FDG uptake in healing bone, lymph nodes, joints, and sites of infection or inflammation.

	TECHNIQUE

Top Abstract INTRODUCTION TECHNIQUE GENERAL DISTRIBUTION OF FDG... SITES OF VARIABLE PHYSIOLOGIC... SITES OF BENIGN PATHOLOGIC... SUMMARY References

 
FDG PET for tumor imaging is typically performed at least 50 minutes after intravenous administration of FDG. This interval allows the increase in tumor tracer activity due to intracellular trapping of FDG (as FDG 6 phosphate) and the concomitant decrease in blood pool and overall background tracer activity to improve tumor-to-background ratios. Although tumor-to-background ratios continue to improve beyond 1 hour after injection (2), the decline in counting statistics due to the physical half-life of F-18 (110 minutes) mandates a compromise between target-to-background ratios and counting statistics; thus, most centers begin emission image acquisitions at approximately 1 hour after injection. The optimal delay between FDG administration and the initiation of the emission image acquisitions has not yet been determined and may be longer than 1 hour for certain tumor imaging applications. The typical dose of FDG in adult patients is 370 MBq (10 mCi), although higher doses approaching 700 MBq are being used. The dose is limited by the dose to the bladder wall because FDG is excreted in the urine (3). Because serum glucose is competitive with FDG, overall image quality and tumor uptake of FDG are diminished by an elevated serum glucose level (4); thus, patients are required to fast for at least 4 hours before the study. Administration of exogenous insulin to reduce the serum glucose level or stimulation of endogenous insulin by means of a meal produces a shift in FDG deposition to insulin-sensitive tissues, including fat and skeletal muscle, with a relative reduction in tumor FDG deposition (5,6).

Currently, the static distribution of FDG is of interest in oncologic FDG imaging for either local-regional diagnosis or staging in the torso or whole body according to the neoplasm or clinical question. Imaging can be performed as emission only (not attenuation corrected) by means of a sequence of contiguous bed positions, and this method is currently most practical for evaluating the whole body (7). Because most lines of coincidence traverse the entire cross section of the body, attenuation effects and distortion are more pronounced in PET of the body than in single photon emission computed tomography (CT) (8); thus, attenuation correction is often employed to produce images with anatomic fidelity for correlation with anatomic images. Attenuation correction requires performance of a transmission scan before or after the emission image acquisition at each corresponding bed position, a requirement that adds time to the overall image acquisition and—with currently available transmission scan technology—adds noise to the final images (9).

Due to the added imaging time and noise in the images, there is some controversy concerning the overall usefulness of attenuation correction for whole-body or whole-torso FDG PET tumor imaging (10,11). For radiologists familiar with CT, attenuation-corrected FDG PET images do provide a more familiar representation of normal anatomic structures and relationships. Nevertheless, many experienced PET imagers have found emission (non–attenuation-corrected) FDG PET body images adequate, even in challenging locations such as the retroperitoneum, as long as proper attention is given to patient preparation (12). Rapid advances in the technology for attenuation correction and image reconstruction software are reducing the time and noise contributions of attenuation correction; thus, it is likely that FDG PET body images will increasingly be routinely attenuation corrected (9,13).

FDG PET images are generally interpreted qualitatively; focal (nonorgan) FDG uptake above blood pool activity at 1 hour on attenuation-corrected images is considered abnormal except in cases of physiologic variants, such as those described in this article. The degree of FDG uptake is often measured to allow comparison within and between different patients and diseases. The standardized uptake value (SUV) has become a widely used method of measuring static FDG accumulation in tissues. The SUV is computed as follows:

Because the SUV is not a true kinetic rate constant, it is often referred to as a semiquantitative measure (14). If all of the tracer were distributed evenly throughout the body, the SUV in every location would be unity. The SUV serves as a normalized target-to-background measure. The SUV of soft tissue is often less than 1.0 (usually about 0.8). Blood pool activity typically has an SUV of 1.5–2.0 at 1 hour after injection, whereas the SUV of the liver is approximately 2.5 and that of the renal cortex is approximately 3.5. The SUV of malignant neoplasms ranges from slightly greater than 2 to as high as 20. FDG avidity varies between different classes of neoplasms. For example, non–small cell lung cancer has relatively high FDG uptake at 1 hour after injection, with an average SUV of 8.2, whereas breast cancer has an average SUV of 3.2 (15). Increased body fat spuriously elevates the SUV; thus, SUVs are increasingly corrected for lean body mass (16). Because the SUV varies with the time after tracer injection, body weight (if correction for lean body mass is not performed), serum glucose level (when elevated), and use of an average pixel value versus a maximum pixel value for the region of interest, SUVs reported in the literature are not entirely comparable unless all of these parameters are specified (17). When a suitably large patient population is studied, cutoff values for benign versus malignant can be determined for a given diagnostic setting such as indeterminant lung nodules; however, such an approach has not generally proved more accurate than qualitative interpretation by an experienced reader (18,19).

In the cases presented in this article, the FDG PET scans were attenuation corrected (unless otherwise noted) and the emission portion of the scan was performed 50–70 minutes after intravenous administration of 370 MBq of FDG. All of the images were obtained with standard dedicated PET scanners (ECAT 931 [Siemens Medical Systems, Iselin, NJ] or Exact 921 [Siemens]) equipped with full-ring bismuth germinate crystal block detectors. Image reconstruction was performed by means of filtered back projection with a Hanning 0.3 postreconstruction filter. SUVs were measured at 1 hour and corrected for lean body mass and are expressed as the average pixel value over the region of interest. The examples are presented as axial, coronal, or sagittal tomographic images or reprojection images. Interpretation generally involves a review of reprojection images, axial and coronal tomographic images, and to a lesser extent sagittal tomographic images on an interactive computer display. Evaluation of structures—including normal variants and pathologic FDG uptake—is often best performed with axial and coronal tomographic images.

	GENERAL DISTRIBUTION OF FDG IN THE BODY

Top Abstract INTRODUCTION TECHNIQUE GENERAL DISTRIBUTION OF FDG... SITES OF VARIABLE PHYSIOLOGIC... SITES OF BENIGN PATHOLOGIC... SUMMARY References

 
FDG accumulation is most intense in the brain, which is dependent on glycolytic metabolism, and in the myocardium, which also relies on glycolytic metabolism in the nonfasting state. Because FDG is excreted in the urine, intense FDG activity is encountered in the intrarenal collecting systems, ureters, and bladder. Less intense tracer activity is present in the liver, spleen, bone marrow, and renal cortex (Fig 1). At 1 hour after tracer injection, blood pool tracer activity results in moderate background tracer activity in the mediastinum, whereas lung activity is low (Fig 2). Although a recent meal (within 4 hours) often causes intense myocardial FDG uptake, fasting by patients for the usual 4–18 hours before FDG administration does not invariably suppress myocardial FDG uptake.

View larger version (77K): [in this window] [in a new window] [Download PPT slide]   Figure 1.  Normal distribution of FDG. Anterior reprojection emission FDG PET image shows the normal distribution of FDG 1 hour after intravenous administration. Intense activity is present in the brain (straight solid arrows) and the bladder (curved arrow). Lower-level activity is present in the liver (open arrow) and kidneys (arrowheads). i = site of FDG injection.

View larger version (81K): [in this window] [in a new window] [Download PPT slide]   Figure 2a.  Normal distribution of FDG. Anterior reprojection attenuation-corrected FDG PET images of the chest and upper abdomen in patients who had fasted show minimal (a) and intense (b) myocardial FDG uptake. With attenuation correction, lung tracer activity is nearly absent and low-level tracer activity is present in the mediastinum and heart cavity due to the blood pool. Low-level hepatic and renal activity is also present. Arrowheads indicate abnormal FDG uptake in small bronchogenic carcinomas.

View larger version (79K): [in this window] [in a new window] [Download PPT slide]   Figure 2b.  Normal distribution of FDG. Anterior reprojection attenuation-corrected FDG PET images of the chest and upper abdomen in patients who had fasted show minimal (a) and intense (b) myocardial FDG uptake. With attenuation correction, lung tracer activity is nearly absent and low-level tracer activity is present in the mediastinum and heart cavity due to the blood pool. Low-level hepatic and renal activity is also present. Arrowheads indicate abnormal FDG uptake in small bronchogenic carcinomas.

	SITES OF VARIABLE PHYSIOLOGIC FDG UPTAKE

Top Abstract INTRODUCTION TECHNIQUE GENERAL DISTRIBUTION OF FDG... SITES OF VARIABLE PHYSIOLOGIC... SITES OF BENIGN PATHOLOGIC... SUMMARY References

View larger version (41K): [in this window] [in a new window] [Download PPT slide]   Figure 3a.  FDG uptake in the stomach. (a, b) Axial (a) and coronal (b) FDG PET images show that FDG uptake in the stomach wall (arrows in b) is readily identified in the presence of gaseous distention. (c) Axial FDG PET image shows that FDG uptake in the stomach wall is readily identified in the presence of a contracted stomach that maintains a gastric configuration. (d, e) Axial FDG PET images show that a laterally situated (d) or medially situated (e) contracted stomach (arrow) can appear as a discrete focal abnormality. In both d and e, there is no other region of FDG uptake to suggest a gastric configuration. i in e = injection site, r = normal renal tracer activity. (f) Axial FDG PET image shows that inhomogeneous FDG uptake in the stomach wall (arrow) can simulate an FDG-avid mass. The faint outline of the stomach is discernible (arrowhead), but the stomach is laterally displaced by hepatomegaly. (g) Axial FDG PET image shows that primary gastric carcinoma (arrow) can also produce inhomogeneous FDG uptake, as can gastric lymphoma. (h) Axial FDG PET image shows that focal, inhomogeneous stomach wall uptake can be simulated by a metastatic lesion of the adjacent left adrenal gland (arrow).

View larger version (92K): [in this window] [in a new window] [Download PPT slide]   Figure 3b.  FDG uptake in the stomach. (a, b) Axial (a) and coronal (b) FDG PET images show that FDG uptake in the stomach wall (arrows in b) is readily identified in the presence of gaseous distention. (c) Axial FDG PET image shows that FDG uptake in the stomach wall is readily identified in the presence of a contracted stomach that maintains a gastric configuration. (d, e) Axial FDG PET images show that a laterally situated (d) or medially situated (e) contracted stomach (arrow) can appear as a discrete focal abnormality. In both d and e, there is no other region of FDG uptake to suggest a gastric configuration. i in e = injection site, r = normal renal tracer activity. (f) Axial FDG PET image shows that inhomogeneous FDG uptake in the stomach wall (arrow) can simulate an FDG-avid mass. The faint outline of the stomach is discernible (arrowhead), but the stomach is laterally displaced by hepatomegaly. (g) Axial FDG PET image shows that primary gastric carcinoma (arrow) can also produce inhomogeneous FDG uptake, as can gastric lymphoma. (h) Axial FDG PET image shows that focal, inhomogeneous stomach wall uptake can be simulated by a metastatic lesion of the adjacent left adrenal gland (arrow).

View larger version (76K): [in this window] [in a new window] [Download PPT slide]   Figure 3c.  FDG uptake in the stomach. (a, b) Axial (a) and coronal (b) FDG PET images show that FDG uptake in the stomach wall (arrows in b) is readily identified in the presence of gaseous distention. (c) Axial FDG PET image shows that FDG uptake in the stomach wall is readily identified in the presence of a contracted stomach that maintains a gastric configuration. (d, e) Axial FDG PET images show that a laterally situated (d) or medially situated (e) contracted stomach (arrow) can appear as a discrete focal abnormality. In both d and e, there is no other region of FDG uptake to suggest a gastric configuration. i in e = injection site, r = normal renal tracer activity. (f) Axial FDG PET image shows that inhomogeneous FDG uptake in the stomach wall (arrow) can simulate an FDG-avid mass. The faint outline of the stomach is discernible (arrowhead), but the stomach is laterally displaced by hepatomegaly. (g) Axial FDG PET image shows that primary gastric carcinoma (arrow) can also produce inhomogeneous FDG uptake, as can gastric lymphoma. (h) Axial FDG PET image shows that focal, inhomogeneous stomach wall uptake can be simulated by a metastatic lesion of the adjacent left adrenal gland (arrow).

View larger version (71K): [in this window] [in a new window] [Download PPT slide]   Figure 3d.  FDG uptake in the stomach. (a, b) Axial (a) and coronal (b) FDG PET images show that FDG uptake in the stomach wall (arrows in b) is readily identified in the presence of gaseous distention. (c) Axial FDG PET image shows that FDG uptake in the stomach wall is readily identified in the presence of a contracted stomach that maintains a gastric configuration. (d, e) Axial FDG PET images show that a laterally situated (d) or medially situated (e) contracted stomach (arrow) can appear as a discrete focal abnormality. In both d and e, there is no other region of FDG uptake to suggest a gastric configuration. i in e = injection site, r = normal renal tracer activity. (f) Axial FDG PET image shows that inhomogeneous FDG uptake in the stomach wall (arrow) can simulate an FDG-avid mass. The faint outline of the stomach is discernible (arrowhead), but the stomach is laterally displaced by hepatomegaly. (g) Axial FDG PET image shows that primary gastric carcinoma (arrow) can also produce inhomogeneous FDG uptake, as can gastric lymphoma. (h) Axial FDG PET image shows that focal, inhomogeneous stomach wall uptake can be simulated by a metastatic lesion of the adjacent left adrenal gland (arrow).

View larger version (68K): [in this window] [in a new window] [Download PPT slide]   Figure 3e.  FDG uptake in the stomach. (a, b) Axial (a) and coronal (b) FDG PET images show that FDG uptake in the stomach wall (arrows in b) is readily identified in the presence of gaseous distention. (c) Axial FDG PET image shows that FDG uptake in the stomach wall is readily identified in the presence of a contracted stomach that maintains a gastric configuration. (d, e) Axial FDG PET images show that a laterally situated (d) or medially situated (e) contracted stomach (arrow) can appear as a discrete focal abnormality. In both d and e, there is no other region of FDG uptake to suggest a gastric configuration. i in e = injection site, r = normal renal tracer activity. (f) Axial FDG PET image shows that inhomogeneous FDG uptake in the stomach wall (arrow) can simulate an FDG-avid mass. The faint outline of the stomach is discernible (arrowhead), but the stomach is laterally displaced by hepatomegaly. (g) Axial FDG PET image shows that primary gastric carcinoma (arrow) can also produce inhomogeneous FDG uptake, as can gastric lymphoma. (h) Axial FDG PET image shows that focal, inhomogeneous stomach wall uptake can be simulated by a metastatic lesion of the adjacent left adrenal gland (arrow).

View larger version (74K): [in this window] [in a new window] [Download PPT slide]   Figure 3f.  FDG uptake in the stomach. (a, b) Axial (a) and coronal (b) FDG PET images show that FDG uptake in the stomach wall (arrows in b) is readily identified in the presence of gaseous distention. (c) Axial FDG PET image shows that FDG uptake in the stomach wall is readily identified in the presence of a contracted stomach that maintains a gastric configuration. (d, e) Axial FDG PET images show that a laterally situated (d) or medially situated (e) contracted stomach (arrow) can appear as a discrete focal abnormality. In both d and e, there is no other region of FDG uptake to suggest a gastric configuration. i in e = injection site, r = normal renal tracer activity. (f) Axial FDG PET image shows that inhomogeneous FDG uptake in the stomach wall (arrow) can simulate an FDG-avid mass. The faint outline of the stomach is discernible (arrowhead), but the stomach is laterally displaced by hepatomegaly. (g) Axial FDG PET image shows that primary gastric carcinoma (arrow) can also produce inhomogeneous FDG uptake, as can gastric lymphoma. (h) Axial FDG PET image shows that focal, inhomogeneous stomach wall uptake can be simulated by a metastatic lesion of the adjacent left adrenal gland (arrow).

View larger version (78K): [in this window] [in a new window] [Download PPT slide]   Figure 3g.  FDG uptake in the stomach. (a, b) Axial (a) and coronal (b) FDG PET images show that FDG uptake in the stomach wall (arrows in b) is readily identified in the presence of gaseous distention. (c) Axial FDG PET image shows that FDG uptake in the stomach wall is readily identified in the presence of a contracted stomach that maintains a gastric configuration. (d, e) Axial FDG PET images show that a laterally situated (d) or medially situated (e) contracted stomach (arrow) can appear as a discrete focal abnormality. In both d and e, there is no other region of FDG uptake to suggest a gastric configuration. i in e = injection site, r = normal renal tracer activity. (f) Axial FDG PET image shows that inhomogeneous FDG uptake in the stomach wall (arrow) can simulate an FDG-avid mass. The faint outline of the stomach is discernible (arrowhead), but the stomach is laterally displaced by hepatomegaly. (g) Axial FDG PET image shows that primary gastric carcinoma (arrow) can also produce inhomogeneous FDG uptake, as can gastric lymphoma. (h) Axial FDG PET image shows that focal, inhomogeneous stomach wall uptake can be simulated by a metastatic lesion of the adjacent left adrenal gland (arrow).

View larger version (75K): [in this window] [in a new window] [Download PPT slide]   Figure 3h.  FDG uptake in the stomach. (a, b) Axial (a) and coronal (b) FDG PET images show that FDG uptake in the stomach wall (arrows in b) is readily identified in the presence of gaseous distention. (c) Axial FDG PET image shows that FDG uptake in the stomach wall is readily identified in the presence of a contracted stomach that maintains a gastric configuration. (d, e) Axial FDG PET images show that a laterally situated (d) or medially situated (e) contracted stomach (arrow) can appear as a discrete focal abnormality. In both d and e, there is no other region of FDG uptake to suggest a gastric configuration. i in e = injection site, r = normal renal tracer activity. (f) Axial FDG PET image shows that inhomogeneous FDG uptake in the stomach wall (arrow) can simulate an FDG-avid mass. The faint outline of the stomach is discernible (arrowhead), but the stomach is laterally displaced by hepatomegaly. (g) Axial FDG PET image shows that primary gastric carcinoma (arrow) can also produce inhomogeneous FDG uptake, as can gastric lymphoma. (h) Axial FDG PET image shows that focal, inhomogeneous stomach wall uptake can be simulated by a metastatic lesion of the adjacent left adrenal gland (arrow).

View larger version (32K): [in this window] [in a new window] [Download PPT slide]   Figure 4a.  FDG uptake in the large intestine. (a, b) Axial (a) and coronal (b) FDG PET images show extensive uptake in the transverse colon (left image in a, right image in b) and cecum (right image in a, left image in b). The inhomogeneity of the FDG accumulation in the transverse colon results in discrete focal abnormalities on the reconstructed images. When isolated, intense focal FDG uptake in the cecum, as in other segments of the colon, can be misinterpreted as an abnormal FDG-avid mass in the abdomen. (c) Axial FDG PET image shows that when the colon is filled with gas, a region of FDG uptake can resemble peritoneal or mesenteric carcinomatosis. (d) Axial FDG PET image of the chest obtained at the lower extent of the field of view shows how a limited field of view can complicate identification of physiologic FDG uptake in the intestine. There is FDG uptake in the hepatic flexure with colonic interposition (arrow), which could be misdiagnosed as a neoplasm in the hepatic dome or costophrenic sulcus. (e, f) Coronal FDG PET image (e) and correlative CT scan (f) clearly show the colon (arrows). This example emphasizes the importance of anatomic correlation with PET results.

View larger version (82K): [in this window] [in a new window] [Download PPT slide]   Figure 4bxy.  FDG uptake in the large intestine. (a, b) Axial (a) and coronal (b) FDG PET images show extensive uptake in the transverse colon (left image in a, right image in b) and cecum (right image in a, left image in b). The inhomogeneity of the FDG accumulation in the transverse colon results in discrete focal abnormalities on the reconstructed images. When isolated, intense focal FDG uptake in the cecum, as in other segments of the colon, can be misinterpreted as an abnormal FDG-avid mass in the abdomen. (c) Axial FDG PET image shows that when the colon is filled with gas, a region of FDG uptake can resemble peritoneal or mesenteric carcinomatosis. (d) Axial FDG PET image of the chest obtained at the lower extent of the field of view shows how a limited field of view can complicate identification of physiologic FDG uptake in the intestine. There is FDG uptake in the hepatic flexure with colonic interposition (arrow), which could be misdiagnosed as a neoplasm in the hepatic dome or costophrenic sulcus. (e, f) Coronal FDG PET image (e) and correlative CT scan (f) clearly show the colon (arrows). This example emphasizes the importance of anatomic correlation with PET results.

View larger version (57K): [in this window] [in a new window] [Download PPT slide]   Figure 4c.  FDG uptake in the large intestine. (a, b) Axial (a) and coronal (b) FDG PET images show extensive uptake in the transverse colon (left image in a, right image in b) and cecum (right image in a, left image in b). The inhomogeneity of the FDG accumulation in the transverse colon results in discrete focal abnormalities on the reconstructed images. When isolated, intense focal FDG uptake in the cecum, as in other segments of the colon, can be misinterpreted as an abnormal FDG-avid mass in the abdomen. (c) Axial FDG PET image shows that when the colon is filled with gas, a region of FDG uptake can resemble peritoneal or mesenteric carcinomatosis. (d) Axial FDG PET image of the chest obtained at the lower extent of the field of view shows how a limited field of view can complicate identification of physiologic FDG uptake in the intestine. There is FDG uptake in the hepatic flexure with colonic interposition (arrow), which could be misdiagnosed as a neoplasm in the hepatic dome or costophrenic sulcus. (e, f) Coronal FDG PET image (e) and correlative CT scan (f) clearly show the colon (arrows). This example emphasizes the importance of anatomic correlation with PET results.

View larger version (49K): [in this window] [in a new window] [Download PPT slide]   Figure 4d.  FDG uptake in the large intestine. (a, b) Axial (a) and coronal (b) FDG PET images show extensive uptake in the transverse colon (left image in a, right image in b) and cecum (right image in a, left image in b). The inhomogeneity of the FDG accumulation in the transverse colon results in discrete focal abnormalities on the reconstructed images. When isolated, intense focal FDG uptake in the cecum, as in other segments of the colon, can be misinterpreted as an abnormal FDG-avid mass in the abdomen. (c) Axial FDG PET image shows that when the colon is filled with gas, a region of FDG uptake can resemble peritoneal or mesenteric carcinomatosis. (d) Axial FDG PET image of the chest obtained at the lower extent of the field of view shows how a limited field of view can complicate identification of physiologic FDG uptake in the intestine. There is FDG uptake in the hepatic flexure with colonic interposition (arrow), which could be misdiagnosed as a neoplasm in the hepatic dome or costophrenic sulcus. (e, f) Coronal FDG PET image (e) and correlative CT scan (f) clearly show the colon (arrows). This example emphasizes the importance of anatomic correlation with PET results.

View larger version (45K): [in this window] [in a new window] [Download PPT slide]   Figure 4e.  FDG uptake in the large intestine. (a, b) Axial (a) and coronal (b) FDG PET images show extensive uptake in the transverse colon (left image in a, right image in b) and cecum (right image in a, left image in b). The inhomogeneity of the FDG accumulation in the transverse colon results in discrete focal abnormalities on the reconstructed images. When isolated, intense focal FDG uptake in the cecum, as in other segments of the colon, can be misinterpreted as an abnormal FDG-avid mass in the abdomen. (c) Axial FDG PET image shows that when the colon is filled with gas, a region of FDG uptake can resemble peritoneal or mesenteric carcinomatosis. (d) Axial FDG PET image of the chest obtained at the lower extent of the field of view shows how a limited field of view can complicate identification of physiologic FDG uptake in the intestine. There is FDG uptake in the hepatic flexure with colonic interposition (arrow), which could be misdiagnosed as a neoplasm in the hepatic dome or costophrenic sulcus. (e, f) Coronal FDG PET image (e) and correlative CT scan (f) clearly show the colon (arrows). This example emphasizes the importance of anatomic correlation with PET results.

View larger version (130K): [in this window] [in a new window] [Download PPT slide]   Figure 4f.  FDG uptake in the large intestine. (a, b) Axial (a) and coronal (b) FDG PET images show extensive uptake in the transverse colon (left image in a, right image in b) and cecum (right image in a, left image in b). The inhomogeneity of the FDG accumulation in the transverse colon results in discrete focal abnormalities on the reconstructed images. When isolated, intense focal FDG uptake in the cecum, as in other segments of the colon, can be misinterpreted as an abnormal FDG-avid mass in the abdomen. (c) Axial FDG PET image shows that when the colon is filled with gas, a region of FDG uptake can resemble peritoneal or mesenteric carcinomatosis. (d) Axial FDG PET image of the chest obtained at the lower extent of the field of view shows how a limited field of view can complicate identification of physiologic FDG uptake in the intestine. There is FDG uptake in the hepatic flexure with colonic interposition (arrow), which could be misdiagnosed as a neoplasm in the hepatic dome or costophrenic sulcus. (e, f) Coronal FDG PET image (e) and correlative CT scan (f) clearly show the colon (arrows). This example emphasizes the importance of anatomic correlation with PET results.

View larger version (39K): [in this window] [in a new window] [Download PPT slide]   Figure 5a.  FDG uptake in the small intestine. (a) Axial FDG PET images (left image obtained at a higher level than right image) show typical segmental FDG uptake in the ileum. FDG uptake is not present elsewhere in the intestine. (b) Axial FDG PET image shows FDG uptake in the terminal ileum and cecum (arrow) with additional isolated foci of uptake in segments of the small intestine (arrowheads); these foci could be mistaken for mesenteric lymph node metastases.

View larger version (31K): [in this window] [in a new window] [Download PPT slide]   Figure 5b.  FDG uptake in the small intestine. (a) Axial FDG PET images (left image obtained at a higher level than right image) show typical segmental FDG uptake in the ileum. FDG uptake is not present elsewhere in the intestine. (b) Axial FDG PET image shows FDG uptake in the terminal ileum and cecum (arrow) with additional isolated foci of uptake in segments of the small intestine (arrowheads); these foci could be mistaken for mesenteric lymph node metastases.

View larger version (19K): [in this window] [in a new window] [Download PPT slide]   Figure 6a.  FDG uptake in the thyroid gland in a nongoitrous, euthyroid patient. Sequential axial FDG PET images (shown from superior [left] to inferior [right]) (a), coronal FDG PET image (left image in b), and sagittal FDG PET image (right image in b) show relatively intense FDG uptake in the thyroid gland.

View larger version (17K): [in this window] [in a new window] [Download PPT slide]   Figure 6b.  FDG uptake in the thyroid gland in a nongoitrous, euthyroid patient. Sequential axial FDG PET images (shown from superior [left] to inferior [right]) (a), coronal FDG PET image (left image in b), and sagittal FDG PET image (right image in b) show relatively intense FDG uptake in the thyroid gland.

View larger version (66K): [in this window] [in a new window] [Download PPT slide]   Figure 7.  FDG uptake in skeletal muscle due to muscle contraction during the FDG uptake phase. Posterior reprojection FDG PET image of a patient who was allowed a short walk after FDG administration shows intense FDG accumulation in the gluteal musculature (arrows).

View larger version (11K): [in this window] [in a new window] [Download PPT slide]   Figure 8.  FDG uptake in skeletal muscle. Coronal FDG PET images of the neck (shown from anterior [left] to posterior [right]) show intense and relatively symmetric FDG activity in portions of the sternocleidomastoid and trapezius muscles (arrowheads).

View larger version (85K): [in this window] [in a new window] [Download PPT slide]   Figure 9a.  Asymmetric or isolated FDG uptake in skeletal muscle. (a) Coronal FDG PET image of a patient who used his left arm before FDG injection reveals FDG uptake in only a small portion of the left trapezius muscle (arrow). (b) Axial FDG PET image of the same patient shows FDG uptake (arrowhead) with an appearance suggestive of a large metastatic or primary neoplasm of the chest wall. (c) Axial FDG PET image shows FDG uptake in the left pterygoid muscle (arrow) in a patient who underwent contralateral neck surgery. Although the patient did not speak during the FDG uptake phase, muscle imbalance due to loss of the contralateral musculature resulted in the FDG uptake, which could be misinterpreted as a neoplasm of the skull base. c = normal cerebellar tracer uptake.

View larger version (21K): [in this window] [in a new window] [Download PPT slide]   Figure 9b.  Asymmetric or isolated FDG uptake in skeletal muscle. (a) Coronal FDG PET image of a patient who used his left arm before FDG injection reveals FDG uptake in only a small portion of the left trapezius muscle (arrow). (b) Axial FDG PET image of the same patient shows FDG uptake (arrowhead) with an appearance suggestive of a large metastatic or primary neoplasm of the chest wall. (c) Axial FDG PET image shows FDG uptake in the left pterygoid muscle (arrow) in a patient who underwent contralateral neck surgery. Although the patient did not speak during the FDG uptake phase, muscle imbalance due to loss of the contralateral musculature resulted in the FDG uptake, which could be misinterpreted as a neoplasm of the skull base. c = normal cerebellar tracer uptake.

View larger version (46K): [in this window] [in a new window] [Download PPT slide]   Figure 9c.  Asymmetric or isolated FDG uptake in skeletal muscle. (a) Coronal FDG PET image of a patient who used his left arm before FDG injection reveals FDG uptake in only a small portion of the left trapezius muscle (arrow). (b) Axial FDG PET image of the same patient shows FDG uptake (arrowhead) with an appearance suggestive of a large metastatic or primary neoplasm of the chest wall. (c) Axial FDG PET image shows FDG uptake in the left pterygoid muscle (arrow) in a patient who underwent contralateral neck surgery. Although the patient did not speak during the FDG uptake phase, muscle imbalance due to loss of the contralateral musculature resulted in the FDG uptake, which could be misinterpreted as a neoplasm of the skull base. c = normal cerebellar tracer uptake.

View larger version (44K): [in this window] [in a new window] [Download PPT slide]   Figure 10xy.  Irregular myocardial FDG uptake in a patient who had fasted for 12 hours before FDG injection. Axial FDG PET images of the chest (shown from superior [top left] to inferior [bottom right]) show the outlines of the left and right ventricles. There are discrete foci of intense FDG activity (arrows), which could be mistaken for mediastinal lymph nodes at the base of the heart.

View larger version (44K): [in this window] [in a new window] [Download PPT slide]   Figure 11axy.  FDG uptake in bone marrow. (a) Axial FDG PET images (shown from superior [top left] to inferior [bottom center]) show normal FDG activity in the marrow of the vertebral bodies (arrows). Sagittal FDG PET image (bottom right) clearly shows the modest FDG uptake at each vertebral body. (b) Axial FDG PET images (shown from superior [top left] to inferior [bottom center]) of a patient with lung cancer show metastases to the marrow spaces of the vertebral bodies (arrowheads) and left pedicle (arrow). Sagittal FDG PET image (bottom right) shows the irregular intensity and nonuniform distribution of the FDG uptake in the metastases. Metastases are also present in the left rib and sternum.

View larger version (41K): [in this window] [in a new window] [Download PPT slide]   Figure 11bxy.  FDG uptake in bone marrow. (a) Axial FDG PET images (shown from superior [top left] to inferior [bottom center]) show normal FDG activity in the marrow of the vertebral bodies (arrows). Sagittal FDG PET image (bottom right) clearly shows the modest FDG uptake at each vertebral body. (b) Axial FDG PET images (shown from superior [top left] to inferior [bottom center]) of a patient with lung cancer show metastases to the marrow spaces of the vertebral bodies (arrowheads) and left pedicle (arrow). Sagittal FDG PET image (bottom right) shows the irregular intensity and nonuniform distribution of the FDG uptake in the metastases. Metastases are also present in the left rib and sternum.

View larger version (31K): [in this window] [in a new window] [Download PPT slide]   Figure 12xy.  FDG uptake in bone marrow in a patient treated with granulocyte colony-stimulating factor. Axial FDG PET images (shown from superior [top left] to inferior [bottom center]) and a sagittal FDG PET image (bottom right) show intense FDG uptake in the vertebral bodies and sternum. The intense uptake resulted from expansion of the bone marrow due to the granulocyte colony-stimulating factor. Marrow activity in the ribs, scapula, and proximal humeri is also evident.

View larger version (41K): [in this window] [in a new window] [Download PPT slide]   Figure 13a.  Urinary excretion of FDG. (a) Axial FDG PET images (left image obtained at a higher level than right image) show the common finding of focal urinary FDG activity in the upper-pole calix of the left kidney (arrowhead). (b) Consecutive axial FDG PET images (shown from superior [top left] to inferior [bottom right]) of a patient with lung cancer show focal urinary FDG activity in the upper-pole calix of the left kidney (arrows) and a metastasis to the left adrenal gland (arrowheads). (c) CT scan of the same patient as in b clearly shows the relationship between the left adrenal mass and the left upper-pole calix. (d, e) Axial FDG PET images (shown from superior [top left] to inferior [bottom right]) (d) and a coronal FDG PET image (e) show isolated urinary FDG activity in a small extrarenal pelvis (arrows). This finding could be misinterpreted as FDG-avid paraaortic or renal hilar lymph nodes if the relationship to the kidney is not clearly demonstrated. (f) Correlative CT scan shows intrapelvic fat with a small, medially displaced ureter (arrow).

View larger version (46K): [in this window] [in a new window] [Download PPT slide]   Figure 13bxy.  Urinary excretion of FDG. (a) Axial FDG PET images (left image obtained at a higher level than right image) show the common finding of focal urinary FDG activity in the upper-pole calix of the left kidney (arrowhead). (b) Consecutive axial FDG PET images (shown from superior [top left] to inferior [bottom right]) of a patient with lung cancer show focal urinary FDG activity in the upper-pole calix of the left kidney (arrows) and a metastasis to the left adrenal gland (arrowheads). (c) CT scan of the same patient as in b clearly shows the relationship between the left adrenal mass and the left upper-pole calix. (d, e) Axial FDG PET images (shown from superior [top left] to inferior [bottom right]) (d) and a coronal FDG PET image (e) show isolated urinary FDG activity in a small extrarenal pelvis (arrows). This finding could be misinterpreted as FDG-avid paraaortic or renal hilar lymph nodes if the relationship to the kidney is not clearly demonstrated. (f) Correlative CT scan shows intrapelvic fat with a small, medially displaced ureter (arrow).

View larger version (135K): [in this window] [in a new window] [Download PPT slide]   Figure 13c.  Urinary excretion of FDG. (a) Axial FDG PET images (left image obtained at a higher level than right image) show the common finding of focal urinary FDG activity in the upper-pole calix of the left kidney (arrowhead). (b) Consecutive axial FDG PET images (shown from superior [top left] to inferior [bottom right]) of a patient with lung cancer show focal urinary FDG activity in the upper-pole calix of the left kidney (arrows) and a metastasis to the left adrenal gland (arrowheads). (c) CT scan of the same patient as in b clearly shows the relationship between the left adrenal mass and the left upper-pole calix. (d, e) Axial FDG PET images (shown from superior [top left] to inferior [bottom right]) (d) and a coronal FDG PET image (e) show isolated urinary FDG activity in a small extrarenal pelvis (arrows). This finding could be misinterpreted as FDG-avid paraaortic or renal hilar lymph nodes if the relationship to the kidney is not clearly demonstrated. (f) Correlative CT scan shows intrapelvic fat with a small, medially displaced ureter (arrow).

View larger version (65K): [in this window] [in a new window] [Download PPT slide]   Figure 13dwxyz.  Urinary excretion of FDG. (a) Axial FDG PET images (left image obtained at a higher level than right image) show the common finding of focal urinary FDG activity in the upper-pole calix of the left kidney (arrowhead). (b) Consecutive axial FDG PET images (shown from superior [top left] to inferior [bottom right]) of a patient with lung cancer show focal urinary FDG activity in the upper-pole calix of the left kidney (arrows) and a metastasis to the left adrenal gland (arrowheads). (c) CT scan of the same patient as in b clearly shows the relationship between the left adrenal mass and the left upper-pole calix. (d, e) Axial FDG PET images (shown from superior [top left] to inferior [bottom right]) (d) and a coronal FDG PET image (e) show isolated urinary FDG activity in a small extrarenal pelvis (arrows). This finding could be misinterpreted as FDG-avid paraaortic or renal hilar lymph nodes if the relationship to the kidney is not clearly demonstrated. (f) Correlative CT scan shows intrapelvic fat with a small, medially displaced ureter (arrow).

View larger version (73K): [in this window] [in a new window] [Download PPT slide]   Figure 13e.  Urinary excretion of FDG. (a) Axial FDG PET images (left image obtained at a higher level than right image) show the common finding of focal urinary FDG activity in the upper-pole calix of the left kidney (arrowhead). (b) Consecutive axial FDG PET images (shown from superior [top left] to inferior [bottom right]) of a patient with lung cancer show focal urinary FDG activity in the upper-pole calix of the left kidney (arrows) and a metastasis to the left adrenal gland (arrowheads). (c) CT scan of the same patient as in b clearly shows the relationship between the left adrenal mass and the left upper-pole calix. (d, e) Axial FDG PET images (shown from superior [top left] to inferior [bottom right]) (d) and a coronal FDG PET image (e) show isolated urinary FDG activity in a small extrarenal pelvis (arrows). This finding could be misinterpreted as FDG-avid paraaortic or renal hilar lymph nodes if the relationship to the kidney is not clearly demonstrated. (f) Correlative CT scan shows intrapelvic fat with a small, medially displaced ureter (arrow).

View larger version (121K): [in this window] [in a new window] [Download PPT slide]   Figure 13f.  Urinary excretion of FDG. (a) Axial FDG PET images (left image obtained at a higher level than right image) show the common finding of focal urinary FDG activity in the upper-pole calix of the left kidney (arrowhead). (b) Consecutive axial FDG PET images (shown from superior [top left] to inferior [bottom right]) of a patient with lung cancer show focal urinary FDG activity in the upper-pole calix of the left kidney (arrows) and a metastasis to the left adrenal gland (arrowheads). (c) CT scan of the same patient as in b clearly shows the relationship between the left adrenal mass and the left upper-pole calix. (d, e) Axial FDG PET images (shown from superior [top left] to inferior [bottom right]) (d) and a coronal FDG PET image (e) show isolated urinary FDG activity in a small extrarenal pelvis (arrows). This finding could be misinterpreted as FDG-avid paraaortic or renal hilar lymph nodes if the relationship to the kidney is not clearly demonstrated. (f) Correlative CT scan shows intrapelvic fat with a small, medially displaced ureter (arrow).

The endometrium can also demonstrate elevated FDG uptake, which should not be confused with a uterine or presacral neoplasm (20). Moderately intense FDG uptake occurs in the testes (Fig 14). This is a normal finding, especially in younger patients, and tends to decline with advancing age (32). Such uptake should not be confused with a primary testicular neoplasm.

View larger version (30K): [in this window] [in a new window] [Download PPT slide]   Figure 14.  FDG uptake in the testes. Axial FDG PET image shows physiologic FDG uptake in the testes.

	SITES OF BENIGN PATHOLOGIC FDG UPTAKE

Top Abstract INTRODUCTION TECHNIQUE GENERAL DISTRIBUTION OF FDG... SITES OF VARIABLE PHYSIOLOGIC... SITES OF BENIGN PATHOLOGIC... SUMMARY References

View larger version (73K): [in this window] [in a new window] [Download PPT slide]   Figure 15awxyz.  FDG uptake in healing bone. (a, b) Axial FDG PET images (shown from superior [top left] to inferior [bottom right]) (a) and a sagittal FDG PET image (b) obtained 6 weeks after cardiac surgery show FDG uptake (SUV = 3.3) in a healing sternum. (c) Axial FDG PET images (left image obtained at a higher level than right image) of a patient who experienced lateral fractures of two right ribs 3 weeks before imaging show FDG uptake (SUV = 2.3) in the healing fractures (arrows). Six weeks later, FDG uptake in the fractures had diminished slightly (SUV = 2.1).

View larger version (109K): [in this window] [in a new window] [Download PPT slide]   Figure 15b.  FDG uptake in healing bone. (a, b) Axial FDG PET images (shown from superior [top left] to inferior [bottom right]) (a) and a sagittal FDG PET image (b) obtained 6 weeks after cardiac surgery show FDG uptake (SUV = 3.3) in a healing sternum. (c) Axial FDG PET images (left image obtained at a higher level than right image) of a patient who experienced lateral fractures of two right ribs 3 weeks before imaging show FDG uptake (SUV = 2.3) in the healing fractures (arrows). Six weeks later, FDG uptake in the fractures had diminished slightly (SUV = 2.1).

View larger version (51K): [in this window] [in a new window] [Download PPT slide]   Figure 15c.  FDG uptake in healing bone. (a, b) Axial FDG PET images (shown from superior [top left] to inferior [bottom right]) (a) and a sagittal FDG PET image (b) obtained 6 weeks after cardiac surgery show FDG uptake (SUV = 3.3) in a healing sternum. (c) Axial FDG PET images (left image obtained at a higher level than right image) of a patient who experienced lateral fractures of two right ribs 3 weeks before imaging show FDG uptake (SUV = 2.3) in the healing fractures (arrows). Six weeks later, FDG uptake in the fractures had diminished slightly (SUV = 2.1).

Lymph Nodes
A major attribute of FDG PET studies is the ability to depict malignant neoplasms in lymph nodes even when the nodes are not pathologically enlarged. However, FDG uptake in lymph nodes is not specific for a malignant neoplasm. Active granulomatous diseases such as tuberculosis and sarcoidosis cause high FDG uptake in involved lymph nodes (34,35). The generalized inflammatory response of regional lymph nodes to infection or recent instrumentation is a common source of elevated FDG uptake in noncancerous lymph nodes (Fig 16). FDG uptake in regional lymph nodes in patients with cancer generally indicates metastatic involvement rather than infection, but either entity can result in FDG uptake (Fig 16b). Abnormal accumulation of FDG in lymph nodes can also be a consequence of spurious delivery of the tracer via lymphatic drainage, as when the tracer extravasates into tissue drained by a regional lymph node group (Fig 17). Owing to the possibility of this minor complication, the site of FDG injection should be contralateral in evaluation of conditions such as breast cancer or melanoma that may metastasize to regional lymph nodes.

View larger version (47K): [in this window] [in a new window] [Download PPT slide]   Figure 16a.  FDG uptake in noncancerous lymph nodes. (a) Axial FDG PET image of a patient with a treated lung abscess shows FDG uptake in intrapulmonary lymph nodes (arrows). Even though the lung abscess is no longer FDG avid, the inflammatory response in the regional lymph nodes and the associated FDG uptake remain. (b) Axial FDG PET images (shown from superior [top left] to inferior [bottom right]) of a patient with a cavitating primary lung neoplasm (open arrow) and adjacent organized pneumonia show FDG uptake in paratracheal and precarinal lymph nodes (solid arrows). The FDG-avid nodes did not harbor metastases but rather an inflammatory response to the regional pneumonia. Note the FDG uptake along the tract formed by a previously placed chest tube (arrowheads). (c) Contrast material–enhanced CT scan of the same patient as in b shows an enlarged precarinal lymph node (solid arrow) and the chest tube tract (open arrow).

View larger version (54K): [in this window] [in a new window] [Download PPT slide]   Figure 16bxy.  FDG uptake in noncancerous lymph nodes. (a) Axial FDG PET image of a patient with a treated lung abscess shows FDG uptake in intrapulmonary lymph nodes (arrows). Even though the lung abscess is no longer FDG avid, the inflammatory response in the regional lymph nodes and the associated FDG uptake remain. (b) Axial FDG PET images (shown from superior [top left] to inferior [bottom right]) of a patient with a cavitating primary lung neoplasm (open arrow) and adjacent organized pneumonia show FDG uptake in paratracheal and precarinal lymph nodes (solid arrows). The FDG-avid nodes did not harbor metastases but rather an inflammatory response to the regional pneumonia. Note the FDG uptake along the tract formed by a previously placed chest tube (arrowheads). (c) Contrast material–enhanced CT scan of the same patient as in b shows an enlarged precarinal lymph node (solid arrow) and the chest tube tract (open arrow).

View larger version (81K): [in this window] [in a new window] [Download PPT slide]   Figure 16c.  FDG uptake in noncancerous lymph nodes. (a) Axial FDG PET image of a patient with a treated lung abscess shows FDG uptake in intrapulmonary lymph nodes (arrows). Even though the lung abscess is no longer FDG avid, the inflammatory response in the regional lymph nodes and the associated FDG uptake remain. (b) Axial FDG PET images (shown from superior [top left] to inferior [bottom right]) of a patient with a cavitating primary lung neoplasm (open arrow) and adjacent organized pneumonia show FDG uptake in paratracheal and precarinal lymph nodes (solid arrows). The FDG-avid nodes did not harbor metastases but rather an inflammatory response to the regional pneumonia. Note the FDG uptake along the tract formed by a previously placed chest tube (arrowheads). (c) Contrast material–enhanced CT scan of the same patient as in b shows an enlarged precarinal lymph node (solid arrow) and the chest tube tract (open arrow).

View larger version (29K): [in this window] [in a new window] [Download PPT slide]   Figure 17.  FDG uptake in a normal lymph node. Axial FDG PET image shows FDG accumulation in a normal axillary lymph node (arrow) secondary to extravasation of the tracer at the injection site, which was in the ipsilateral arm.

View larger version (86K): [in this window] [in a new window] [Download PPT slide]   Figure 18a.  FDG uptake in joints. (a) Axial FDG PET image of a patient with no clinical or radiographic evidence of abnormal sternoclavicular joints shows focal FDG uptake in the sternoclavicular joints (arrows). (b) Axial FDG PET images (shown from superior [left] to inferior [right]) show elevated FDG uptake in the anterior rib ends (arrows). Arrowheads = vertebral body metastasis.

View larger version (21K): [in this window] [in a new window] [Download PPT slide]   Figure 18b.  FDG uptake in joints. (a) Axial FDG PET image of a patient with no clinical or radiographic evidence of abnormal sternoclavicular joints shows focal FDG uptake in the sternoclavicular joints (arrows). (b) Axial FDG PET images (shown from superior [left] to inferior [right]) show elevated FDG uptake in the anterior rib ends (arrows). Arrowheads = vertebral body metastasis.

View larger version (43K): [in this window] [in a new window] [Download PPT slide]   Figure 19a.  FDG uptake in joints. (a) Axial FDG PET image shows symmetric focal FDG uptake (SUV = 3.2) in the inferior glenohumeral joints (arrows). (b, c) Axial (b) and coronal (c) FDG PET images show isolated focal FDG uptake (SUV = 3.0) (arrowhead), which mimics an osseous metastasis.

View larger version (73K): [in this window] [in a new window] [Download PPT slide]   Figure 19b.  FDG uptake in joints. (a) Axial FDG PET image shows symmetric focal FDG uptake (SUV = 3.2) in the inferior glenohumeral joints (arrows). (b, c) Axial (b) and coronal (c) FDG PET images show isolated focal FDG uptake (SUV = 3.0) (arrowhead), which mimics an osseous metastasis.

View larger version (44K): [in this window] [in a new window] [Download PPT slide]   Figure 19c.  FDG uptake in joints. (a) Axial FDG PET image shows symmetric focal FDG uptake (SUV = 3.2) in the inferior glenohumeral joints (arrows). (b, c) Axial (b) and coronal (c) FDG PET images show isolated focal FDG uptake (SUV = 3.0) (arrowhead), which mimics an osseous metastasis.

View larger version (65K): [in this window] [in a new window] [Download PPT slide]   Figure 20a.  FDG uptake associated with infection. (a, b) Coronal (a) and axial (b) FDG PET images of a patient with pneumonia in the right middle lobe show diffuse FDG uptake (arrow). The configuration and uniformity of the uptake are typical of uncomplicated alveolar pneumonia. (c) Correlative CT scan shows the alveolar pneumonia. (d, e) Coronal (d) and axial (e) FDG PET images of a patient with cavitating pneumonia show focal, intense FDG uptake (arrow). (f) Correlative CT scan shows the cavitating pneumonia.

View larger version (40K): [in this window] [in a new window] [Download PPT slide]   Figure 20b.  FDG uptake associated with infection. (a, b) Coronal (a) and axial (b) FDG PET images of a patient with pneumonia in the right middle lobe show diffuse FDG uptake (arrow). The configuration and uniformity of the uptake are typical of uncomplicated alveolar pneumonia. (c) Correlative CT scan shows the alveolar pneumonia. (d, e) Coronal (d) and axial (e) FDG PET images of a patient with cavitating pneumonia show focal, intense FDG uptake (arrow). (f) Correlative CT scan shows the cavitating pneumonia.

View larger version (98K): [in this window] [in a new window] [Download PPT slide]   Figure 20c.  FDG uptake associated with infection. (a, b) Coronal (a) and axial (b) FDG PET images of a patient with pneumonia in the right middle lobe show diffuse FDG uptake (arrow). The configuration and uniformity of the uptake are typical of uncomplicated alveolar pneumonia. (c) Correlative CT scan shows the alveolar pneumonia. (d, e) Coronal (d) and axial (e) FDG PET images of a patient with cavitating pneumonia show focal, intense FDG uptake (arrow). (f) Correlative CT scan shows the cavitating pneumonia.

View larger version (57K): [in this window] [in a new window] [Download PPT slide]   Figure 20d.  FDG uptake associated with infection. (a, b) Coronal (a) and axial (b) FDG PET images of a patient with pneumonia in the right middle lobe show diffuse FDG uptake (arrow). The configuration and uniformity of the uptake are typical of uncomplicated alveolar pneumonia. (c) Correlative CT scan shows the alveolar pneumonia. (d, e) Coronal (d) and axial (e) FDG PET images of a patient with cavitating pneumonia show focal, intense FDG uptake (arrow). (f) Correlative CT scan shows the cavitating pneumonia.

View larger version (44K): [in this window] [in a new window] [Download PPT slide]   Figure 20e.  FDG uptake associated with infection. (a, b) Coronal (a) and axial (b) FDG PET images of a patient with pneumonia in the right middle lobe show diffuse FDG uptake (arrow). The configuration and uniformity of the uptake are typical of uncomplicated alveolar pneumonia. (c) Correlative CT scan shows the alveolar pneumonia. (d, e) Coronal (d) and axial (e) FDG PET images of a patient with cavitating pneumonia show focal, intense FDG uptake (arrow). (f) Correlative CT scan shows the cavitating pneumonia.

View larger version (119K): [in this window] [in a new window] [Download PPT slide]   Figure 20f.  FDG uptake associated with infection. (a, b) Coronal (a) and axial (b) FDG PET images of a patient with pneumonia in the right middle lobe show diffuse FDG uptake (arrow). The configuration and uniformity of the uptake are typical of uncomplicated alveolar pneumonia. (c) Correlative CT scan shows the alveolar pneumonia. (d, e) Coronal (d) and axial (e) FDG PET images of a patient with cavitating pneumonia show focal, intense FDG uptake (arrow). (f) Correlative CT scan shows the cavitating pneumonia.

View larger version (25K): [in this window] [in a new window] [Download PPT slide]   Figure 21.  FDG uptake associated with ostomy. Axial FDG PET image shows FDG uptake at the exposed mucosa of a healing tracheostomy owing to a normal inflammatory response.

View larger version (43K): [in this window] [in a new window] [Download PPT slide]   Figure 22a.  FDG uptake associated with granulation tissue. (a) Axial FDG PET image of a patient with a resolving sterile hematoma in the right breast due to lumpectomy shows a rim of FDG uptake (arrows). (b) Axial FDG PET image of a patient with a resolving thromboembolism of the left main pulmonary artery shows modest FDG activity (arrow).

View larger version (27K): [in this window] [in a new window] [Download PPT slide]   Figure 22b.  FDG uptake associated with granulation tissue. (a) Axial FDG PET image of a patient with a resolving sterile hematoma in the right breast due to lumpectomy shows a rim of FDG uptake (arrows). (b) Axial FDG PET image of a patient with a resolving thromboembolism of the left main pulmonary artery shows modest FDG activity (arrow).

	SUMMARY

Top Abstract INTRODUCTION TECHNIQUE GENERAL DISTRIBUTION OF FDG... SITES OF VARIABLE PHYSIOLOGIC... SITES OF BENIGN PATHOLOGIC... SUMMARY References

	Footnotes

 
This article meets the criteria for 1.0 credit hour in category 1 of the AMA Physician's Recognition Award. To obtain credit, see the questionnaire on pp 147–154.

Supported by the Ann Arbor Veterans Affairs Medical Center; R.L.W. supported by grants CA52880, CA53172, and CA56731 from the National Institutes of Health.

Address reprint requests to P.D.S.

This article meets the criteria for 1.0 credit hour in category 1 of the AMA Physician's Recognition Award. To obtain credit, see the questionnaire on pp 147–154.

**. Multiple body systems

Abbreviations: FDG = 2-[F-18]fluoro-2-deoxy-D-glucose PET = positron emission tomography SUV = standardized uptake value

CME FEATURE This article meets the criteria for 1.0 credit hour in category 1 of the AMA Physician's Recognition Award. To obtain credit, see the questionnaire on pp 147–154.

LEARNING OBJECTIVES After reading this article and taking the test, the reader will be able to: • List portions of the digestive tract that can demonstrate physiologic uptake of FDG and describe typical intensity, pattern, and possible associated misinterpretations for each. • Explain why myocardial uptake of FDG is variable in fasted patients and potential interpretive pitfalls that can occur when myocardial FDG uptake is non-uniform. • List causes of skeletal muscle FDG uptake and strategies for patient preparation that minimize it. • Describe interpretive pitfalls associated with urinary excretion of FDG and suggest maneuvers that may minimize such. • List five pathologic causes of focal FDG uptake that are not due to malignant neoplasm but could be misinterpreted as primary or metastatic cancer.

Received for publication March 4, 1998. Revision received May 1, 1998. September 29, 1998. Accepted for publication October 13, 1998.

	References

Top Abstract INTRODUCTION TECHNIQUE GENERAL DISTRIBUTION OF FDG... SITES OF VARIABLE PHYSIOLOGIC... SITES OF BENIGN PATHOLOGIC... SUMMARY References

 

1. Rigo P, Paulus P, Kaschten BJ, et al. Oncologic applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23:1641-1674.[Medline]
2. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?. J Nucl Med 1994; 35:1308-1312.[Abstract/Free Full Text]
3. Jones SC, Alavi A, Christman D, Montanez I, Wolf AP, Reivich M. The radiation dosimetry of 2-[F-18] fluoro-2-deoxy-d-glucose in man. J Nucl Med 1982; 23:613-617.[Abstract/Free Full Text]
4. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med 1993; 34:1-6.[Abstract/Free Full Text]
5. Minn H, Leskinen-Kallio S, Lindholm P, et al. [¹⁸F] fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J Comput Assist Tomogr 1993; 17:115-123.
6. Torizuka T, Fisher SJ, Wahl RL. Insulin-induced hypoglycemia decreases uptake of 2-[F-18]fluoro-2-deoxy-d-glucose into experimental mammary carcinoma. Radiology 1997; 203:169-172.[Abstract/Free Full Text]
7. Dahlbom M, Hoffman EJ, Hoh CK, et al. Whole-body positron emission tomography: methods and performance characteristics. J Nucl Med 1992; 33:1191-1199.[Abstract/Free Full Text]
8. Zasadny KR, Kison PV, Quint LE, Wahl RL. Untreated lung cancer: quantification of systematic distortion of tumor size and shape on non–attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET scans. Radiology 1996; 201:873-876.[Abstract/Free Full Text]
9. Bailey DL. Transmission scanning in emission tomography. Eur J Nucl Med 1998; 25:774-787.[Medline]
10. Bengel FM, Ziegler SI, Avril N, Weber W, Laubenbacher C, Schwaiger M. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med 1997; 24:1091-1098.[Medline]
11. Imran MB, Kubota K, Yamada S, et al. Lesion-to-background ratio in non–attenuation-corrected whole-body FDG PET images. J Nucl Med 1998; 39:1219-1223.[Medline]
12. Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. RadioGraphics 1998; 18:805-823.[Abstract]
13. Bedigian MP, Benard F, Smith RJ, Karp JS, Alavi A. Whole-body positron emission tomography for oncology imaging using singles transmission scanning with segmentation and ordered subsets–expectation maximization (OS-EM) reconstruction. Eur J Nucl Med 1998; 25:659-661.[Medline]
14. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?. J Nucl Med 1994; 35:1308-1312.
15. Torizuka T, Zasadny KR, Recker B, Wahl RL. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 1998; 207:767-774.[Abstract/Free Full Text]
16. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-850.[Abstract/Free Full Text]
17. Keyes JW, Jr. SUV: standard uptake or silly useless value?. J Nucl Med 1995; 36:1836-1839.[Free Full Text]
18. Stollfuss JC, Glatting G, Friess H, Kocher F, Beger HG, Reske SN. 2-(fluorine-18)-fluoro-2-deoxy-d-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995; 195:339-344.[Abstract/Free Full Text]
19. Lowe VJ, Fletcher JW, Gobar L. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16:1075-1084.[Abstract]
20. Brigid GA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. AJR 1997; 169:1675-1680.[Free Full Text]
21. Meyer MA. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin Nucl Med 1995; 20:434-435.[Medline]
22. Miraldi F, Vesselle H, Faulhaber PF, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 1998; 23:3-7.[Medline]
23. Conti PS, Durski JM, Singer PA, Austin T. Incidence of thyroid gland uptake of F-18 FDG in cancer patients (abstr). Radiology 1997; 205(P):220.
24. Jabour BA, Choi Y, Hoh CK, et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-d-glucose and MR imaging correlation. Radiology 1993; 186:27-35.[Abstract/Free Full Text]
25. Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine-18-FDG: effect on oral diazepam. J Nucl Med 1996; 37:1127-1129.[Abstract/Free Full Text]
26. Kostakoglu L, Wong JCH, Barrington SF, Cronin BF, Dynes AM, Maisey MN. Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med 1996; 37:1771-1773.[Abstract/Free Full Text]
27. Mossberg KA, Mommessin JI, Taegtmeyer H. Skeletal muscle glucose uptake during short-term contractile activity in vivo: effect of prior contractions. Metabolism 1993; 42:1609-1616.[Medline]
28. Cook GJR, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; 26:308-314.[Medline]
29. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37:441-446.[Abstract/Free Full Text]
30. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heat muscle. Annu Rev Physiol 1974; 36:413-459.
31. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Pre-clinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998; 16:173-180.[Abstract/Free Full Text]
32. Kosuda S, Fisher S, Kison PV, Wahl RL, Grossman HB. Uptake of 2-deoxy-2-[¹⁸F]fluoro-d-glucose in the normal testis: retrospective PET study and animal experiment. Ann Nucl Med 1997; 11:195-199.[Medline]
33. Meyer M, Gast T, Raja S, Hubner K. Increased F-18 FDG accumulation in an acute fracture. Clin Nucl Med 1994; 19:13-14.[Medline]
34. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35:1647-1649.[Abstract/Free Full Text]
35. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23:1409-1415.[Medline]
36. Tahara T, Ichiya Y, Kuwabara U, et al. High [18F]-fluorodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr 1989; 13:829-831.[Medline]
37. Yasuda S, Shohtsu A, Ide M, Takagi S, Kijima H, Horiuchi M. Elevated F-18 FDG uptake in plasmacyte-rich chronic maxillary sinusitis. Clin Nucl Med 1998; 23:176-178.[Medline]
38. Shreve PD. Focal flourine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998; 25:259-264.[Medline]
39. Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2[¹⁸F]-fluoro-2-deoxy-d-glucose positron emission tomography. Gut 1995; 36:771-777.[Abstract/Free Full Text]

This article has been cited by other articles:

				S. Nishizawa, S. Kojima, S. Teramukai, M. Inubushi, H. Kodama, Y. Maeda, H. Okada, B. Zhou, Y. Nagai, and M. Fukushima Prospective Evaluation of Whole-Body Cancer Screening With Multiple Modalities Including [18F]Fluorodeoxyglucose Positron Emission Tomography in a Healthy Population: A Preliminary Report J. Clin. Oncol., April 10, 2009; 27(11): 1767 - 1773. [Abstract] [Full Text] [PDF]

				J. J. Fox and H. W. Strauss One Step Closer to Imaging Vulnerable Plaque in the Coronary Arteries J. Nucl. Med., April 1, 2009; 50(4): 497 - 500. [Full Text] [PDF]

				Z. Keidar, A. Gurman-Balbir, D. Gaitini, and O. Israel Fever of Unknown Origin: The Role of 18F-FDG PET/CT J. Nucl. Med., December 1, 2008; 49(12): 1980 - 1985. [Abstract] [Full Text] [PDF]

				J. B. Roedl, R. R. Colen, K. King, A. J. Fischman, P. R. Mueller, and M. A. Blake Visual PET/CT Scoring for Nonspecific 18F-FDG Uptake in the Differentiation of Early Malignant and Benign Esophageal Lesions Am. J. Roentgenol., August 1, 2008; 191(2): 515 - 521. [Abstract] [Full Text] [PDF]

				J. Y. Kwak, E.-K. Kim, M. Yun, A. Cho, M. J. Kim, E. J. Son, and K. K. Oh Thyroid Incidentalomas Identified by 18F-FDG PET: Sonographic Correlation Am. J. Roentgenol., August 1, 2008; 191(2): 598 - 603. [Abstract] [Full Text] [PDF]

				A. K. Buck, K. Herrmann, C. M. z. Buschenfelde, M. E. Juweid, M. Bischoff, G. Glatting, G. Weirich, P. Moller, H.-J. Wester, K. Scheidhauer, et al. Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine Clin. Cancer Res., May 15, 2008; 14(10): 2970 - 2977. [Abstract] [Full Text] [PDF]

				G. Williams and G. M. Kolodny Method for Decreasing Uptake of 18F-FDG by Hypermetabolic Brown Adipose Tissue on PET Am. J. Roentgenol., May 1, 2008; 190(5): 1406 - 1409. [Abstract] [Full Text] [PDF]

				J. W. Fletcher, B. Djulbegovic, H. P. Soares, B. A. Siegel, V. J. Lowe, G. H. Lyman, R. E. Coleman, R. Wahl, J. C. Paschold, N. Avril, et al. Recommendations on the Use of 18F-FDG PET in Oncology J. Nucl. Med., March 1, 2008; 49(3): 480 - 508. [Abstract] [Full Text] [PDF]

				G. Williams and G. M. Kolodny Suppression of Myocardial 18F-FDG Uptake by Preparing Patients with a High-Fat, Low-Carbohydrate Diet Am. J. Roentgenol., February 1, 2008; 190(2): W151 - W156. [Abstract] [Full Text] [PDF]

				B. Atassi, A. K. Bangash, A. Bahrani, G. Pizzi, R. J. Lewandowski, R. K. Ryu, K. T. Sato, V. L. Gates, M. F. Mulcahy, L. Kulik, et al. Multimodality Imaging Following 90Y Radioembolization: A Comprehensive Review and Pictorial Essay RadioGraphics, January 1, 2008; 28(1): 81 - 99. [Abstract] [Full Text] [PDF]

				H. S. Lim, W. Yoon, T. W. Chung, J. K. Kim, J. G. Park, H. K. Kang, H. S. Bom, and J. H. Yoon FDG PET/CT for the Detection and Evaluation of Breast Diseases: Usefulness and Limitations RadioGraphics, October 1, 2007; 27(suppl_1): S197 - S213. [Abstract] [Full Text] [PDF]

				F. Wang, Z. Wang, W. Yao, H. Xie, J. Xu, and L. Tian Role of 99mTc-Octreotide Acetate Scintigraphy in Suspected Lung Cancer Compared with 18F-FDG Dual-Head Coincidence Imaging J. Nucl. Med., September 1, 2007; 48(9): 1442 - 1448. [Abstract] [Full Text] [PDF]

				K. Strobel, R. Dummer, D. B. Husarik, M. Perez Lago, T. F. Hany, and H. C. Steinert High-Risk Melanoma: Accuracy of FDG PET/CT with Added CT Morphologic Information for Detection of Metastases Radiology, August 1, 2007; 244(2): 566 - 574. [Abstract] [Full Text] [PDF]

				K. Herrmann, H. A. Wieder, A. K. Buck, M. Schoffel, B.-J. Krause, F. Fend, T. Schuster, C. Meyer zum Buschenfelde, H.-J. Wester, J. Duyster, et al. Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma Clin. Cancer Res., June 15, 2007; 13(12): 3552 - 3558. [Abstract] [Full Text] [PDF]

				D. Karantanis, T. V. Bogsrud, G. A. Wiseman, B. P. Mullan, R. M. Subramaniam, M. A. Nathan, P. J. Peller, R. S. Bahn, and V. J. Lowe Clinical Significance of Diffusely Increased 18F-FDG Uptake in the Thyroid Gland J. Nucl. Med., June 1, 2007; 48(6): 896 - 901. [Abstract] [Full Text] [PDF]

				W. De Wever, Y. Vankan, S. Stroobants, and J. Verschakelen Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer Eur. Respir. J., May 1, 2007; 29(5): 995 - 1002. [Abstract] [Full Text] [PDF]

				C. Are, J. F. Hsu, H. Schoder, J. P. Shah, S. M. Larson, and A. R. Shaha FDG-PET Detected Thyroid Incidentalomas: Need for Further Investigation? Ann. Surg. Oncol., January 1, 2007; 14(1): 239 - 247. [Abstract] [Full Text] [PDF]

				K Fukuchi, H Ohta, K Matsumura, and Y Ishida Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies Br. J. Radiol., January 1, 2007; 80(949): 3 - 11. [Abstract] [Full Text] [PDF]

				J. D. Berry and G. J. R. Cook Positron emission tomography in oncology Br. Med. Bull., December 14, 2006; (2006) ldl013v1. [Abstract] [Full Text] [PDF]

				A. K. Buck, M. Bommer, S. Stilgenbauer, M. Juweid, G. Glatting, H. Schirrmeister, T. Mattfeldt, D. Tepsic, D. Bunjes, F. M. Mottaghy, et al. Molecular Imaging of Proliferation in Malignant Lymphoma. Cancer Res., November 15, 2006; 66(22): 11055 - 11061. [Abstract] [Full Text] [PDF]

				B. Rodriguez-Vigil, N. Gomez-Leon, I. Pinilla, D. Hernandez-Maraver, J. Coya, L. Martin-Curto, and R. Madero PET/CT in Lymphoma: Prospective Study of Enhanced Full-Dose PET/CT Versus Unenhanced Low-Dose PET/CT J. Nucl. Med., October 1, 2006; 47(10): 1643 - 1648. [Abstract] [Full Text] [PDF]

				I. Serganova, J. Humm, C. Ling, and R. Blasberg Tumor hypoxia imaging. Clin. Cancer Res., September 15, 2006; 12(18): 5260 - 5264. [Full Text] [PDF]

				K. Yasufuku, T. Nakajima, K. Motoori, Y. Sekine, K. Shibuya, K. Hiroshima, and T. Fujisawa Comparison of Endobronchial Ultrasound, Positron Emission Tomography, and CT for Lymph Node Staging of Lung Cancer. Chest, September 1, 2006; 130(3): 710 - 718. [Abstract] [Full Text] [PDF]

				M. A. Blake, A. Singh, B. N. Setty, J. Slattery, M. Kalra, M. M. Maher, D. V. Sahani, A. J. Fischman, and P. R. Mueller Pearls and Pitfalls in Interpretation of Abdominal and Pelvic PET-CT RadioGraphics, September 1, 2006; 26(5): 1335 - 1353. [Abstract] [Full Text] [PDF]

				H.-E. Wang, H.-M. Yu, R.-S. Liu, M. Lin, J. G. Gelovani, J.-J. Hwang, H.-J. Wei, and W.-P. Deng Molecular Imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for Monitoring Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Prodrug Activation Gene Therapy of Cancer J. Nucl. Med., July 1, 2006; 47(7): 1161 - 1171. [Abstract] [Full Text] [PDF]

				S. Wachter, S. Tomek, A. Kurtaran, N. Wachter-Gerstner, B. Djavan, A. Becherer, M. Mitterhauser, G. Dobrozemsky, S. Li, R. Potter, et al. 11C-Acetate Positron Emission Tomography Imaging and Image Fusion With Computed Tomography and Magnetic Resonance Imaging in Patients With Recurrent Prostate Cancer J. Clin. Oncol., June 1, 2006; 24(16): 2513 - 2519. [Abstract] [Full Text] [PDF]

				R. S. Jackson, T. C. Schlarman, W. L. Hubble, and M. M. Osman Prevalence and Patterns of Physiologic Muscle Uptake Detected with Whole-Body 18F-FDG PET. J. Nucl. Med. Technol., March 1, 2006; 34(1): 29 - 33. [Abstract] [Full Text] [PDF]

				T. Bunyaviroch and R. E. Coleman PET Evaluation of Lung Cancer J. Nucl. Med., March 1, 2006; 47(3): 451 - 469. [Full Text] [PDF]

				C. S. Yap, J. Czernin, M. C. Fishbein, R. B. Cameron, C. Schiepers, M. E. Phelps, and W. A. Weber Evaluation of Thoracic Tumors With 18F-Fluorothymidine and 18F- Fluorodeoxyglucose-Positron Emission Tomography. Chest, February 1, 2006; 129(2): 393 - 401. [Abstract] [Full Text] [PDF]

				A. van Waarde, P. L. Jager, K. Ishiwata, R. A. Dierckx, and P. H. Elsinga Comparison of Sigma-Ligands and Metabolic PET Tracers for Differentiating Tumor from Inflammation J. Nucl. Med., January 1, 2006; 47(1): 150 - 154. [Abstract] [Full Text] [PDF]

				J. Ames, T. Blodgett, and C. Meltzer 18F-FDG Uptake in an Ovary Containing a Hemorrhagic Corpus Luteal Cyst: False-Positive PET/CT in a Patient with Cervical Carcinoma Am. J. Roentgenol., October 1, 2005; 185(4): 1057 - 1059. [Full Text] [PDF]

				M. M. Abouzied, E. S. Crawford, and H. A. Nabi 18F-FDG Imaging: Pitfalls and Artifacts J. Nucl. Med. Technol., September 1, 2005; 33(3): 145 - 155. [Abstract] [Full Text] [PDF]

				C. Love, M. B. Tomas, G. G. Tronco, and C. J. Palestro FDG PET of Infection and Inflammation RadioGraphics, September 1, 2005; 25(5): 1357 - 1368. [Abstract] [Full Text] [PDF]

				H Prosch, S Mirzaei, E Oschatz, G Strasser, M Huber, and G Mostbeck Gluteal injection site granulomas: false positive finding on FDG-PET in patients with non-small cell lung cancer Br. J. Radiol., August 1, 2005; 78(932): 758 - 761. [Abstract] [Full Text] [PDF]

				J. G. Yi, E. M. Marom, R. F. Munden, M. T. Truong, H. A. Macapinlac, G. W. Gladish, B. S. Sabloff, and D. A. Podoloff Focal Uptake of Fluorodeoxyglucose by the Thyroid in Patients Undergoing Initial Disease Staging with Combined PET/CT for Non-Small Cell Lung Cancer Radiology, July 1, 2005; 236(1): 271 - 275. [Abstract] [Full Text] [PDF]

				T. M. Blodgett, M. B. Fukui, C. H. Snyderman, B. F. Branstetter IV, B. M. McCook, D. W. Townsend, and C. C. Meltzer Combined PET-CT in the Head and Neck: Part 1. Physiologic, Altered Physiologic, and Artifactual FDG Uptake RadioGraphics, July 1, 2005; 25(4): 897 - 912. [Abstract] [Full Text] [PDF]

				N. Subhas, P. V. Patel, H. K. Pannu, H. A. Jacene, E. K. Fishman, and R. L. Wahl Imaging of Pelvic Malignancies with In-Line FDG PET-CT: Case Examples and Common Pitfalls of FDG PET RadioGraphics, July 1, 2005; 25(4): 1031 - 1043. [Abstract] [Full Text] [PDF]

				Z. Cheng, A. Mahmood, H. Li, A. Davison, and A. G. Jones [99mTcOAADT]-(CH2)2-NEt2: A Potential Small-Molecule Single-Photon Emission Computed Tomography Probe for Imaging Metastatic Melanoma Cancer Res., June 15, 2005; 65(12): 4979 - 4986. [Abstract] [Full Text] [PDF]

				M. Yun, H. S. Choi, E. Yoo, J. K. Bong, Y. H. Ryu, and J. D. Lee The Role of Gastric Distention in Differentiating Recurrent Tumor from Physiologic Uptake in the Remnant Stomach on 18F-FDG PET J. Nucl. Med., June 1, 2005; 46(6): 953 - 957. [Abstract] [Full Text] [PDF]

				O. Israel, N. Yefremov, R. Bar-Shalom, O. Kagana, A. Frenkel, Z. Keidar, and D. Fischer PET/CT Detection of Unexpected Gastrointestinal Foci of 18F-FDG Uptake: Incidence, Localization Patterns, and Clinical Significance J. Nucl. Med., May 1, 2005; 46(5): 758 - 762. [Abstract] [Full Text] [PDF]

				G. Brix, U. Lechel, G. Glatting, S. I. Ziegler, W. Munzing, S. P. Muller, and T. Beyer Radiation Exposure of Patients Undergoing Whole-Body Dual-Modality 18F-FDG PET/CT Examinations J. Nucl. Med., April 1, 2005; 46(4): 608 - 613. [Abstract] [Full Text] [PDF]

				G. Antoch, F. M. Vogt, P. Veit, L. S. Freudenberg, N. Blechschmid, O. Dirsch, A. Bockisch, M. Forsting, J. F. Debatin, and H. Kuehl Assessment of Liver Tissue After Radiofrequency Ablation: Findings with Different Imaging Procedures J. Nucl. Med., March 1, 2005; 46(3): 520 - 525. [Abstract] [Full Text] [PDF]

				V. Kapoor, M. B. Fukui, and B. M. McCook Role of 18FFDG PET/CT in the Treatment of Head and Neck Cancers: Principles, Technique, Normal Distribution, and Initial Staging Am. J. Roentgenol., February 1, 2005; 184(2): 579 - 587. [Full Text] [PDF]

				P. Y. Salaun, R. K. Grewal, I. Dodamane, H. W. Yeung, S. M. Larson, and H. W. Strauss An Analysis of the 18F-FDG Uptake Pattern in the Stomach J. Nucl. Med., January 1, 2005; 46(1): 48 - 51. [Abstract] [Full Text] [PDF]

				A. M. Groves, H. K. Cheow, T. Win, and K. K. Balan Extensive Skeletal Muscle Uptake of 18F-FDG: Relation to Immunosuppressants? J. Nucl. Med. Technol., December 1, 2004; 32(4): 206 - 208. [Abstract] [Full Text] [PDF]

				F. Y.-I. Lee, J. Yu, S.-S. Chang, R. Fawwaz, and M. V. Parisien Diagnostic Value and Limitations of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Cartilaginous Tumors of Bone J. Bone Joint Surg. Am., December 1, 2004; 86(12): 2677 - 2685. [Abstract] [Full Text] [PDF]

				C. Love, S. E. Marwin, M. B. Tomas, E. S. Krauss, G. G. Tronco, K. K. Bhargava, K. J. Nichols, and C. J. Palestro Diagnosing Infection in the Failed Joint Replacement: A Comparison of Coincidence Detection 18F-FDG and 111In-Labeled Leukocyte/99mTc-Sulfur Colloid Marrow Imaging J. Nucl. Med., November 1, 2004; 45(11): 1864 - 1871. [Abstract] [Full Text] [PDF]

				B. Ferdinand, P. Gupta, and E. L. Kramer Spectrum of Thymic Uptake at 18F-FDG PET RadioGraphics, November 1, 2004; 24(6): 1611 - 1616. [Abstract] [Full Text] [PDF]

				H. Schirrmeister, M. Hetzel, J. Hetzel, T. Habig, C. Schumann, M. Bommer, P. Blum, H. von Beauvais, and A. Babiak Challenging Manifestations of Malignancies: CASE 3. Fibrinous Tracheitis: An Uncommon Manifestation of Hodgkin's Lymphoma J. Clin. Oncol., September 1, 2004; 22(17): 3642 - 3643. [Full Text] [PDF]

				L. Kostakoglu, R. Hardoff, R. Mirtcheva, and S. J. Goldsmith PET-CT Fusion Imaging in Differentiating Physiologic from Pathologic FDG Uptake RadioGraphics, September 1, 2004; 24(5): 1411 - 1431. [Abstract] [Full Text] [PDF]

				K. Pacak, G. Eisenhofer, and D. S. Goldstein Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography Endocr. Rev., August 1, 2004; 25(4): 568 - 580. [Abstract] [Full Text] [PDF]

				J.W. B. de Groot, Th.P. Links, P.L. Jager, T. Kahraman, and J.Th. M. Plukker Impact of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients with Biochemical Evidence of Recurrent or Residual Medullary Thyroid Cancer Ann. Surg. Oncol., August 1, 2004; 11(8): 786 - 794. [Abstract] [Full Text] [PDF]

				A. van Waarde, D. C.P. Cobben, A. J.H. Suurmeijer, B. Maas, W. Vaalburg, E. F.J. de Vries, P. L. Jager, H. J. Hoekstra, and P. H. Elsinga Selectivity of 18F-FLT and 18F-FDG for Differentiating Tumor from Inflammation in a Rodent Model J. Nucl. Med., April 1, 2004; 45(4): 695 - 700. [Abstract] [Full Text] [PDF]

				G. Antoch, G. M. Kaiser, A. B. Mueller, K. A. Metz, H. Zhang, H. Kuehl, S. Westermann, C. E. Broelsch, S. P. Mueller, A. Bockisch, et al. Intraoperative Radiation Therapy in Liver Tissue in a Pig Model: Monitoring with Dual-Modality PET/CT Radiology, March 1, 2004; 230(3): 753 - 760. [Abstract] [Full Text] [PDF]

				H. Agress Jr and B. Z. Cooper Detection of Clinically Unexpected Malignant and Premalignant Tumors with Whole-Body FDG PET: Histopathologic Comparison Radiology, February 1, 2004; 230(2): 417 - 422. [Abstract] [Full Text] [PDF]

				R. L. Wahl Why Nearly All PET of Abdominal and Pelvic Cancers Will Be Performed as PET/CT J. Nucl. Med., January 1, 2004; 45(90010): 82S - 95. [Abstract] [Full Text] [PDF]

				H. K. Pannu, R. E. Bristow, C. Cohade, E. K. Fishman, and R. L. Wahl PET-CT in Recurrent Ovarian Cancer: Initial Observations RadioGraphics, January 1, 2004; 24(1): 209 - 223. [Abstract] [Full Text] [PDF]

				H. L. van Westreenen, P. A.M. Heeren, P. L. Jager, H. M. van Dullemen, H. Groen, and J. Th.M. Plukker Pitfalls of Positive Findings in Staging Esophageal Cancer With F-18-Fluorodeoxyglucose Positron Emission Tomography Ann. Surg. Oncol., November 1, 2003; 10(9): 1100 - 1105. [Abstract] [Full Text] [PDF]

				A. K. Buck, G. Halter, H. Schirrmeister, J. Kotzerke, I. Wurziger, G. Glatting, T. Mattfeldt, B. Neumaier, S. N. Reske, and M. Hetzel Imaging Proliferation in Lung Tumors with PET: 18F-FLT Versus 18F-FDG J. Nucl. Med., September 1, 2003; 44(9): 1426 - 1431. [Abstract] [Full Text] [PDF]

				R. L. Titton, D. A. Gervais, G. W. Boland, M. M. Maher, and P. R. Mueller Sonography and Sonographically Guided Fine-Needle Aspiration Biopsy of the Thyroid Gland: Indications and Techniques, Pearls and Pitfalls Am. J. Roentgenol., July 1, 2003; 181(1): 267 - 271. [Full Text] [PDF]

				L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith Clinical Role of FDG PET in Evaluation of Cancer Patients RadioGraphics, March 1, 2003; 23(2): 315 - 340. [Abstract] [Full Text] [PDF]

				C. Cohade, M. Osman, H. K. Pannu, and R. L. Wahl Uptake in Supraclavicular Area Fat ("USA-Fat"): Description on 18F-FDG PET/CT J. Nucl. Med., February 1, 2003; 44(2): 170 - 176. [Abstract] [Full Text] [PDF]

				T. F. Hany, H. C. Steinert, G. W. Goerres, A. Buck, and G. K. von Schulthess PET Diagnostic Accuracy: Improvement with In-Line PET-CT System: Initial Results Radiology, November 1, 2002; 225(2): 575 - 581. [Abstract] [Full Text] [PDF]

				C.-S. Liu, Y.-Y. Shen, C.-C. Lin, R.-F. Yen, and C.-H. Kao Clinical Impact of [18F]FDG-PET in Patients with Suspected Recurrent Breast Cancer Based on Asymptomatically Elevated Tumor Marker Serum Levels: a Preliminary Report Jpn. J. Clin. Oncol., July 1, 2002; 32(7): 244 - 247. [Abstract] [Full Text] [PDF]

				E. M. Kamel, G. W. Goerres, C. Burger, G. K. von Schulthess, and H. C. Steinert Recurrent Laryngeal Nerve Palsy in Patients with Lung Cancer: Detection with PET-CT Image Fusion—Report of Six Cases Radiology, July 1, 2002; 224(1): 153 - 156. [Abstract] [Full Text]

				A. K. Buck, H. Schirrmeister, M. Hetzel, M. von der Heide, G. Halter, G. Glatting, T. Mattfeldt, F. Liewald, S. N. Reske, and B. Neumaier 3-Deoxy-3-[18F]Fluorothymidine-Positron Emission Tomography for Noninvasive Assessment of Proliferation in Pulmonary Nodules Cancer Res., June 1, 2002; 62(12): 3331 - 3334. [Abstract] [Full Text] [PDF]

				B. A. Siegel, L. P. Adler, R. L. Wahl, A. Williams, N. DeSouza, and A. M. Peters FDG Positron Emission Tomography Detection of Pelvic Nodal Metastases in Gynecologic Cancer Am. J. Roentgenol., March 1, 2002; 178 (3): 762 - 764. [Full Text] [PDF]

				T. Mochizuki, E. Tsukamoto, Y. Kuge, K. Kanegae, S. Zhao, K. Hikosaka, M. Hosokawa, M. Kohanawa, and N. Tamaki FDG Uptake and Glucose Transporter Subtype Expressions in Experimental Tumor and Inflammation Models J. Nucl. Med., October 1, 2001; 42(10): 1551 - 1555. [Abstract] [Full Text] [PDF]

				I. A. Zealley, S. J. Skehan, J. Rawlinson, G. Coates, C. Nahmias, and S. Somers Selection of Patients for Resection of Hepatic Metastases: Improved Detection of Extrahepatic Disease with FDG PET RadioGraphics, October 1, 2001; 21(90001): S55 - 69. [Abstract] [Full Text] [PDF]

				T. Inoue, K. Koyama, N. Oriuchi, S. Alyafei, Z. Yuan, H. Suzuki, K. Takeuchi, Y. Tomaru, K. Tomiyoshi, J. Aoki, et al. Detection of Malignant Tumors: Whole-Body PET with Fluorine 18 {{alpha}}-Methyl Tyrosine versus FDG—Preliminary Study Radiology, July 1, 2001; 220(1): 54 - 62. [Abstract] [Full Text] [PDF]

				P. Willkomm, H. Bender, M. Bangard, P. Decker, F. Grunwald, and H.-J. Biersack FDG PET and Immunoscintigraphy with 99mTc-Labeled Antibody Fragments for Detection of the Recurrence of Colorectal Carcinoma J. Nucl. Med., October 1, 2000; 41(10): 1657 - 1663. [Abstract] [Full Text] [PDF]

				S. J. Skehan, A. L. Brown, M. Thompson, J. E. M. Young, G. Coates, and C. Nahmias Imaging Features of Primary and Recurrent Esophageal Cancer at FDG PET RadioGraphics, May 1, 2000; 20(3): 713 - 723. [Abstract] [Full Text] [PDF]

This Article Abstract Figures Only Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shreve, P. D. Articles by Wahl, R. L. Search for Related Content PubMed PubMed Citation Articles by Shreve, P. D. Articles by Wahl, R. L.